A Phase 4 interventional study of Rosuvastatin+Ezetimibe and Rosuvastatin in Diabetes Mellitus and Hypercholesterolemia, sponsored by Yuhan Corporation. Completed at 4 sites in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-23.
Sponsored by Yuhan Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing rosuvastatin in Diabetes Mellitus — 1 open to participants now, 1 under way, none of them phase 3. rosuvastatin · Diabetes Mellitus.
Among the 17 studies testing rosuvastatin in Diabetes Mellitus, this one is the 12th largest by enrollment, is one of 2 that started in 2017, is one of 9 in phase 4, and was the 15th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.
Browse Diabetes Mellitus studies →1 of the 17 studies testing rosuvastatin in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:
Shaheed Benazir Bhutto University Sheringal Dir Upper · Sites in Pakistan
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.
This study: 19 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 85 is close to the median of 80 across 6,024 interventional studies indexed under Diabetes Mellitus.
Median enrollment 108 across the 17 interventional studies. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 17 have an industry lead sponsor. The 10 most frequent:
Yuhan Corporation is the lead sponsor of 110 studies on the registry; 8 are open to participants now.
Yuhan Corporation has 3 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
1 of the studies testing rosuvastatin in Diabetes Mellitus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07378293Shaheed Benazir Bhutto University Sheringal Dir UpperEffects of Selected Statins on Blood Glucose Levels in Healthy Volunteers | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing rosuvastatin in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Study to Compare Rosuvastatin/Ezetimibe Combination and Monotherapy in Patients with Diabetes Mellitus and Hypercholesterolemia.
This trial is conducted to compare the efficacy and safety between Rosuvastatin/Ezetimibe combination and Rosuvastatin monotherapy in patients with Diabetes Mellitus and Hypercholesterolemia for 8 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rosuvastatin 5mg+Ezetimibe 10mg Rosuvamibe ® Tablet, 1T, Once a day/8week
Drug: Rosuvastatin+Ezetimibe
Rosuvastatin 5mg Monorova ® Tablet, 1T, Once a day/8week
Drug: Rosuvastatin
Drug pages: Rosuvastatin · Ezetimibe
Rosuvastatin 5mg+Ezetimibe 10mg
Also known as: Rosuvamibe ® 10/5mg
Rosuvastatin 5Mg Tablet
Also known as: Monorova ® 5mg
Low density lipoprotein cholesterol (LDL-C) (%)
The rate of change(%) of LDL-C at Week 8 compared to the baseline
Time frame: baseline, Week 8
Low density lipoprotein cholesterol (LDL-C) (100mg/dL)
The ratio of patients who reached the treatment target (100mg/dL) of LDL-C at Week 8 compared to the baseline
Time frame: baseline, Week 8
HbA1C, Glycated albumin, Homeostasis model assessment Insulin resistance(HOMA-IR), Homeostasis model assessment ß cell(HOMA-ß) resistance(HOMA-IR), Homeostasis model assessment ß cell(HOMA-ß)
Variation of HbA1C, Glycated albumin, Homeostasis model assessment Insulin resistance(HOMA-IR), Homeostasis model assessment ß cell(HOMA-ß) at Week 8 compared to the baseline resistance(HOMA-IR), Homeostasis model assessment ß cell(HOMA-ß) change form the baseline at Week 8
Time frame: baseline, Week 8
LDL-C, Non HDL-C, HDL-C, Triglyceride(TG), Total cholesterol(TC), Apolipoprotein A1, Apolipoprotein B, Lipid ratios (LDL-C/HDL-C, TC/HDL-C, Non- HDL-C/HDL-C) Apolipoprotein A1, Apolipoprotein B, Lipid ratios (LDL-C/HDL-C, TC/HDL-C, Non- HDL-C/HDL-C)
Variation of LDL-C, Non HDL-C, HDL-C, Triglyceride(TG), Total cholesterol(TC), Apolipoprotein A1, Apolipoprotein B, Lipid ratios (LDL-C/HDL-C, TC/HDL-C, Non- HDL-C/HDL-C) at Week 8 compared to the baseline Apolipoprotein A1, Apolipoprotein B, Lipid ratios (LDL-C/HDL-C, TC/HDL-C, Non- HDL-C/HDL-C) change form the base line at Week 8
Time frame: baseline, Week 8
Thiobarbituric acid reactive substances(TBARs)
Absolute value change of Thiobarbituric acid reactive substances(TBARs) at Week 8 compared to baseline to baseline.
Time frame: baseline, Week 8
Fibroblast Growth Factor 21
Absolute value change of Fibroblast Growth Factor 21 at Week 8 compared to baseline.
Time frame: baseline, Week 8
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2017 to primary completion in Apr 2019, 19 months.
Of 48 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's 19 months is above that.
Counting every sponsor, half of 197 studies reached it within 24 months; a quarter within 13 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rosuvastatin · Ezetimibe